NYLIM
CHRS icon

New York Life Investment Management’s Coherus Oncology CHRS Stock Holding History

New York Life Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-155,036
Closed -$371K – 947
2024
Q1 		$371K Buy
155,036
+105,079
+210% +$259K ﹤0.01% 974
2023
Q4 		$166K Sell
49,957
-2,096
-4% -$5.61K ﹤0.01% 1298
2023
Q3 		$195K Sell
52,053
-8,201
-14% -$37.9K ﹤0.01% 1275
2023
Q2 		$257K Sell
60,254
-12,650
-17% -$74.6K ﹤0.01% 1269
2023
Q1 		$499K Buy
+72,904
New +$566K 0.01% 679

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

New York Life Investment Management's CHRS Position: Q2 2024 in Review

New York Life Investment Management sold out of Coherus Oncology (CHRS) in Q2 2024, closing a stake of 155,036 shares — an estimated $371K sold.

New York Life Investment Management first reported a position in CHRS in Q1 2023 and held it in 5 quarters. The position peaked at $499K in Q1 2023. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

  • New York Life Investment Management reported no remaining Coherus Oncology position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 155,036 Coherus Oncology shares in Q2 2024, an estimated $371K.
  • New York Life Investment Management first reported a position in Coherus Oncology in Q1 2023 and held it in 5 quarters.
  • New York Life Investment Management's Coherus Oncology position peaked at $499K in Q1 2023.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.